強皮症の世界市場レポート 2024

強皮症の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.5%の年間複合成長率（CAGR）で29億7,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、生物学的治療の出現、精密医療の進歩、幹細胞治療の開発、ゲノミクスとバイオマーカーの進行中の調査、および世界の協力の増加によるものと考えられます。予測期間中に予想される主な動向には、デジタルヘルスソリューションの採用、マイクロバイオームへの注目の高まり、患者中心のケアへの移行、再生医療の進歩、健康の公平性とアクセスの強化などが含まれます。

強皮症の普及率の増加により、強皮症市場は前進しています。 強皮症は、異常なコラーゲン増殖を特徴とする慢性自己免疫疾患であり、さまざまな環境要因の影響を受けた可能性のある、無秩序な免疫応答によって引き起こされます。症例数が増加するにつれて、診断と治療の強化の重要性が明らかになります。効果的な強皮症治療法は、免疫反応を調節し、環境危険因子への曝露を軽減することによって病気を管理し、症状を軽減するために非常に重要です。たとえば、2022年 6月のKarger Publishersのレポートによると、英国では19,000人が強皮症を持っており、世界の有病者数は250万人に達しました。さらに、2021年7月にオックスフォード・アカデミック・プレスが発表した調査論文では、世界の有病率は10万人当たり17.6人、発生率は10万人年当たり1.4人であることが明らかになった。したがって、強皮症の普及の増加が強皮症市場の原動力となっています。

毒素への曝露の影響により、強皮症市場はさらに推進されています。毒素への曝露には、生体系に悪影響を与える可能性のある有害物質の接触または摂取が含まれます。 強皮症市場は、調査を推進し、標的療法を開発し、環境的および遺伝的誘因となる可能性のある症状である強皮症の影響を受ける患者のケアを改善することにより、毒素への曝露に対処する上で重要な役割を果たしています。たとえば、米国に本拠を置く国家毒物管理システムであるポイズンコントロールが2023年1月に発表した報告書では、208万件を超える人の毒物暴露が明らかになり、その75.5％は意図的ではなく、2021年には6歳未満の子供が1,000人当たり37.0人の毒物暴露を占めていることが明らかになりました。対照的に、前年の2020年には、報告された毒物暴露の83%が米国毒物センターによって無毒であるとみなされました。したがって、毒素への曝露が強皮症市場を牽引し続けています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の強皮症市場、治療別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 薬剤
• 手術
• その他の治療
• 世界の強皮症市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 全身性強皮症
• 限局性強皮症
• 世界の強皮症市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 病院
• 薬局
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の強皮症市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の強皮症市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 強皮症市場の競合情勢
• 強皮症市場の企業プロファイル
  • Pfizer Inc.
  • Johnson And Johnson Inc.
  • F. Hoffmann-La Roche AG
  • AbbVie Inc.
  • Bayer AG

第31章 その他の大手および革新的な企業

• Novartis AG
• Merck And Co. Inc.
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• GSK plc
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Aspen Pharmacare Holdings Limited
• Boehringer Ingelheim International GmbH
• Principia Biopharma Corp

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Scleroderma is an uncommon autoimmune disease characterized by the chronic and rare abnormal growth of collagen, a protein responsible for forming the structural framework of the skin and other tissues. Various treatments aim to address the excessive production of collagen, either providing cures, halting its overproduction, effectively managing associated symptoms, or reducing the risk of complications linked to scleroderma.

The primary treatments for scleroderma encompass medication, surgery, and other therapeutic approaches. Medication involves the use of substances, typically in the form of drugs or pharmaceuticals, intended to prevent, treat, or manage medical conditions, diseases, or symptoms. Hospitals, pharmaceutical stores, and other healthcare providers commonly administer medications, specifically indicated for treating both systemic scleroderma and localized scleroderma.

The scleroderma market research report is one of a series of new reports from The Business Research Company that provides scleroderma market statistics, including scleroderma industry global market size, regional shares, competitors with a scleroderma market share, detailed scleroderma market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma industry. This scleroderma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The scleroderma market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be ascribed to progress in diagnostic methods, advancements in immunological research, developments in therapeutic approaches, increased awareness and education, and genetic studies.

The scleroderma market size is expected to see strong growth in the next few years. It will grow to $2.97 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be credited to the emergence of biological therapies, advancements in precision medicine, the development of stem cell therapies, ongoing research in genomics and biomarkers, and increased global collaborations. Major trends expected in the forecast period include the adoption of digital health solutions, a heightened focus on the microbiome, a shift towards patient-centric care, advancements in regenerative medicine, and a stronger emphasis on health equity and access.

The increasing prevalence of scleroderma is propelling the scleroderma market forward. Scleroderma, characterized by abnormal collagen growth, is a chronic autoimmune disease triggered by an unregulated immune response, possibly influenced by various environmental factors. As the number of cases rises, the significance of enhanced diagnosis and treatment becomes apparent. Effective scleroderma therapeutics are crucial for managing the illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors. For instance, a report by Karger Publishers in June 2022 indicated that 19,000 people had scleroderma in the UK, and the global prevalence reached 2.5 million people. Additionally, a research article published by Oxford Academic Press in July 2021 revealed a global prevalence of 17.6 cases per 100,000 people and an incidence rate of 1.4 cases per 100,000 person-years. Hence, the increasing prevalence of scleroderma is a driving force in the scleroderma market.

The impact of toxin exposure is further propelling the scleroderma market. Toxin exposure involves contact or ingestion of harmful substances that can negatively affect biological systems. The scleroderma market plays a crucial role in addressing toxin exposure by advancing research, developing targeted therapies, and improving patient care for those affected by scleroderma, a condition with potential environmental and genetic triggers. For example, a report by Poison Control in January 2023, a U.S.-based national poison control system, revealed over 2.08 million human poison exposures, with 75.5% being unintentional, and children under six accounting for 37.0 poison exposures per 1,000 children in 2021. In contrast, the previous year, 2020, saw 83% of reported poison exposures deemed nontoxic by U.S. poison centers. Thus, the exposure to toxins continues to drive the scleroderma market.

The development of novel treatments is a prominent trend gaining traction in the scleroderma market. Leading companies in the market are actively engaged in creating innovative drugs to effectively manage symptoms and maintain their market position. For example, in April 2022, Tyr Pharma Inc., a biotherapeutics manufacturer based in the US, secured regulatory approval from the US Food and Drug Administration for its groundbreaking systemic sclerosis-related interstitial lung disease drug, efzofitimod. This First-in-class immunomodulator targets the neuropilin-2 (NRP2) receptor to downregulate and control the immune response, offering relief from scleroderma symptoms. Moreover, efzofitimod demonstrated efficacy in reducing pro-inflammatory markers in a clinical study involving patients with pulmonary sarcoidosis, further highlighting its potential impact.

Major companies operating in the scleroderma market are emphasizing product launches, including a clinical trial platform, to advance scleroderma treatments and identify promising agents for progression from Phase IIb to Phase III. A clinical trial platform serves as a comprehensive infrastructure facilitating the concurrent assessment of multiple therapies across various clinical trials. In August 2023, The Scleroderma Research Foundation (SRF), a non-profit organization based in the US, introduced CONQUEST, a groundbreaking clinical trial platform. With a global reach spanning 130 centers in 22 countries, CONQUEST employs a master protocol to evaluate multiple therapies simultaneously. This initiative is poised to significantly impact the scleroderma market by accelerating the development and approval of effective therapies through its collaborative and efficient clinical evaluation approach.

In November 2021, Sanofi S.A., a pharmaceutical company based in France, completed the acquisition of Kadmon Holdings for approximately $1.9 billion. This strategic move aims to enhance Sanofi's medicine business and better cater to its customer base. Additionally, Sanofi plans to continue the development of Belumosudil, Kadmon's investigational therapy for treating diffuse cutaneous systemic sclerosis (dcSSc). Kadmon Holdings, based in the US, specializes in discovering, developing, and marketing transformative medicines for disease areas with significant unmet medical needs.

Major companies operating in the scleroderma market report are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., Celgene Corporation, Actelion Pharmaceuticals Inc., H.A.C. Pharma

North America was the largest region in the scleroderma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the scleroderma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The scleroderma market consists of revenues earned by entities by providing dilation of blood vessels, immunosuppressants, relieving pain, and reducing infection. The market value includes the value of related goods sold by the service provider or included within the service offering. The scleroderma market also includes the sales of methotrexate, anti-thymocyte globulin, mycophenolate mofetil, and cyclophosphamide. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Scleroderma Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on scleroderma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for scleroderma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The scleroderma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment: Medication; Surgery; Other Treatments
• 2) By Indication: Systemic Scleroderma; Localized Scleroderma
• 3) By End User: Hospital; Pharmaceutical Stores; Other End Users
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Inc.; F. Hoffmann-La Roche AG; Abbvie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Scleroderma Market Characteristics

3. Scleroderma Market Trends And Strategies

4. Scleroderma Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Scleroderma Market Size and Growth

• 5.1. Global Scleroderma Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Scleroderma Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Scleroderma Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Scleroderma Market Segmentation

• 6.1. Global Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medication
• Surgery
• Other Treatments
• 6.2. Global Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Systemic Scleroderma
• Localized Scleroderma
• 6.3. Global Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital
• Pharmaceutical Stores
• Other End Users

7. Scleroderma Market Regional And Country Analysis

• 7.1. Global Scleroderma Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Scleroderma Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Scleroderma Market

• 8.1. Asia-Pacific Scleroderma Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Scleroderma Market

• 9.1. China Scleroderma Market Overview
• 9.2. China Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Scleroderma Market

• 10.1. India Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Scleroderma Market

• 11.1. Japan Scleroderma Market Overview
• 11.2. Japan Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Scleroderma Market

• 12.1. Australia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Scleroderma Market

• 13.1. Indonesia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Scleroderma Market

• 14.1. South Korea Scleroderma Market Overview
• 14.2. South Korea Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Scleroderma Market

• 15.1. Western Europe Scleroderma Market Overview
• 15.2. Western Europe Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Scleroderma Market

• 16.1. UK Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Scleroderma Market

• 17.1. Germany Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Scleroderma Market

• 18.1. France Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Scleroderma Market

• 19.1. Italy Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Scleroderma Market

• 20.1. Spain Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Scleroderma Market

• 21.1. Eastern Europe Scleroderma Market Overview
• 21.2. Eastern Europe Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Scleroderma Market

• 22.1. Russia Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Scleroderma Market

• 23.1. North America Scleroderma Market Overview
• 23.2. North America Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Scleroderma Market

• 24.1. USA Scleroderma Market Overview
• 24.2. USA Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Scleroderma Market

• 25.1. Canada Scleroderma Market Overview
• 25.2. Canada Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Scleroderma Market

• 26.1. South America Scleroderma Market Overview
• 26.2. South America Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Scleroderma Market

• 27.1. Brazil Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Scleroderma Market

• 28.1. Middle East Scleroderma Market Overview
• 28.2. Middle East Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Scleroderma Market

• 29.1. Africa Scleroderma Market Overview
• 29.2. Africa Scleroderma Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Scleroderma Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Scleroderma Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Scleroderma Market Competitive Landscape And Company Profiles

• 30.1. Scleroderma Market Competitive Landscape
• 30.2. Scleroderma Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson And Johnson Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. AbbVie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Scleroderma Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Merck And Co. Inc.
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. AstraZeneca plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Amgen Inc.
• 31.10. GSK plc
• 31.11. Teva Pharmaceutical Industries Ltd.
• 31.12. Astellas Pharma Inc.
• 31.13. Aspen Pharmacare Holdings Limited
• 31.14. Boehringer Ingelheim International GmbH
• 31.15. Principia Biopharma Corp

32. Global Scleroderma Market Competitive Benchmarking

33. Global Scleroderma Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Scleroderma Market

35. Scleroderma Market Future Outlook and Potential Analysis

• 35.1 Scleroderma Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Scleroderma Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Scleroderma Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer